Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses. Issue 2 (February 2016)

• Record Type: Journal Article
• Authors: Zenda, Sadamoto; Akimoto, Tetsuo; Mizumoto, Masashi; Hayashi, Ryuichi; Arahira, Satoko; Okumura, Toshiyuki; Sakurai, Hideyuki
• Is Part Of: Radiotherapy and oncology. Volume 118:Issue 2(2016:Feb.)
• Page Start: 267
• Page End: 271
• Publication Date: 2016-02
• Subjects: Proton beam therapy -- Mucosal melanoma -- Rare disease -- Nasal cavity -- Head and neck cancer; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2015.10.025
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Purpose: The aim of this phase II study was to assess the clinical benefit of proton beam therapy for mucosal melanoma of the nasal cavity and para-nasal sinuses. Materials and methods: N0M0 mucosal melanoma of the nasal cavity and para-nasal sinuses were enrolled. Proton therapy was delivered three times per week with a planned total dose of 60 GyE in 15 fractions. Primary endpoint was local control rate at 1 year after treatment. Based on the results of a pilot study, the local control rate was estimated at 75%. Results: Thirty-two patients were enrolled from June 2008 through October 2012. Patient characteristics were as follows: median age 73 years (range, 36–89 years); male/female ratio, 12/20; and T stage 3/4, 11/21. Local control rate at 1 year was 75.8% (95% CI: 63.8–92.4%). With a median follow-up period of 36.4 months, 3-year overall survival rate was 46.1%. The most frequent pattern of first failure was distant metastasis. The main cause of death was cancer death due to distant metastases (93.3%). Conclusions: Proton beam therapy showed sufficient local control benefits for mucosal melanoma as an alternative treatment of surgery.